Risk factors of gastric cancer as a basis for the development of a prognostic questionnaire for the register of patients with precancerous gastroduodenal diseases
https://doi.org/10.31146/1682-8658-ecg-205-9-29-38
Abstract
The article is a critical analysis of the world scientific literature devoted to the search for risk factors for stomach cancer for the timely prognosis of this disease and the implementation of cancer prevention measures. The paper presents data from numerous studies to determine the role of environmental factors, including unfavorable ecology, as well as gender, age, smoking, alcohol abuse. The authors’ opinions are presented on the essential role of the alimentary factor in the genesis of neoplasms in the stomach, including the predominance of animal fats in food, the abuse of overcooked, pickled foods rich in nitrosoamines, foods saturated with spices, the use of too hot food, the use of foods infected with mycotoxins in nutrition. The role of environmental factors in the prognosis of gastric cancer is noted: the state of secretory activity of the stomach, the dynamics of inflammatory and atrophic processes in the mucous membrane. A special role for the prognosis of stomach cancer is assigned by many authors to the pyloric helicobacter, as well as the quantitative indicator of glycated blood hemoglobin and its dynamics. The significance of genetic changes in the genesis of gastric cancer and their role as prognostic factors of the disease is ambiguous. The article draws attention to the multidirectional results of many authors in understanding a large number of factors they have studied that could be used as prognostic witnesses of stomach cancer. The expediency of searching for the most significant regional factors for the prognosis of gastric cancer is substantiated, on the basis of which it is very important to create registers of patients with precancerous diseases of the stomach for the organization and implementation of personalized and effective measures of cancer prevention.
About the Authors
A. Yu. Baranovskiy
St. Petersburg State University
Russian Federation
Russian Federation
T. L. Tcvetkova
Novel SPb LLC
Russian Federation
Russian Federation
References
1. Bray F. B., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018, no. 70, pp. 313. doi: 10.3322/caac.21492.
2. Kaprin A., Starinskiy V., Shakhzadova A., et al. The state of cancer care for the population of Russia in 2018. - Moscow: MNIOI them. P. A. Herzen - branch of the Federal State Budgetary Institution “National Medical Research Center of Radiology” of the Ministry of Health of Russia, 2019. (in Russ.) ISBN 5-85502-024-X @@Каприн А. Д., В. В. Старинский В. В., Шахзадова А. О. (Ред.) Состояние онкологической помощи населению России в 2018 году. - Москва: МНИОИ им. П. А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019.
3. Besova N., Kalinin A., Nered S., et al. Stomach cancer. Clinical guidelines. Moscow, 2020. КР574 (in Russ.) @@Бесова Н. С., Калинин А. Е., Неред С. Н. и соавт. Рак желудка. Клинические рекомендации. М., 2020
4. GLOBOCAN 2020 Graph production: IARC (https://gco.iarc.fr/today) World Health Organization
5. Kaprin A., Starinskiy V., Shakhzadova A., et al. The state of cancer care for the population of Russia in 2019, M. MNIOI them. P. A. Herzen - branch of the Federal State Budgetary Institution “National Medical Research Center of Radiology” of the Ministry of Health of Russia, 2020, pp. 239. (in Russ.) @@Каприн А. Д., В. В. Старинский В. В., Шахзадова А. О. (Ред.) Состояние онкологической помощи населению России в 2019 году. - М.: МНИОИ им. П. А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. - 239 с.
6. Taninaga J., Nishiyama Y., Fujibayashi K., et al. Prediction of future gastric cancer risk using a machine learning algorithm and comprehensive medical check-up data: a case-control study. Scientific Reports, 2019, no.9, pp. 1-9. doi: 10.1038/s41598-019-48769.
7. Yang P., Zhou Y., Chen B., et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. European journal of cancer, 2009, no. 45, pp. 2867-2873. doi: 10.1016/j.ejca.2009.04.019.
8. Inoue M., Iwasaki M., Otani T., et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Archives of internal medicine. 2006, no. 166, pp. 1871-1877. doi: 10.1001/archinte.166.17.1871.
9. Ilson D. H. Advances in the treatment of gastric cancer. Current opinion in gastroenterology. 2017, no. 33, pp. 473-476. doi: 10.1097/MOG.0000000000000475.
10. Kim G.H., Liang, P.S., Bang S. J., et al. Screening and surveillance for gastric cancer in the United States: Is it needed? Gastrointestinal endoscopy. 2016, no. 84, pp. 18-28. doi: 10.1016/j.gie.2016.02.028.
11. Cai Q., Zhu C., Yuan Y., et al. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study. Gut, 2019, no. 68, pp. 1576-1587. doi: 10.1136/gutjnl-2018-317556.
12. Yaghoobi M., Mcnabb-Baltar J., Bijarchi R., et al. What is the quantitative risk of gastric cancer in the first-degree relatives of patients? A meta-analysis. World journal of gastroenterology. 2017, no. 23, pp. 2435-42. doi: 10.3748/wjg.v23.i13.2435.
13. Bernini M., Barbi S., Roviello F., et al. Family history of gastric cancer: a correlation between epidemiologic findings and clinical data. Gastric Cancer. 2006, no. 9, pp. 9-13. doi: 10.1007/s10120-005-0350-7.
14. Tu H., Sun L., Dong X., et al. А Serological Biopsy Using Five Stomach-Specific circulating Biomarkers for gastric cancer risk assessment: a Multi-Phase Study. American Journal of Gastroenterology, 2017, no. 112, pp. 704-715. doi:10.1038/ajg.2017.55.
15. Hua X. Сonsensus on screening and endoscopic diagnosis and treatment of early gastric cancer in Сhina. Chinese society of digestive endoscopy. 2014, no. 31, pp. 361-77. doi:10.1155/2016/9638041.
16. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori igg antibody and serum pepsinogen levels - “aBc method”. Proceedings of the Japan Academy. 2011, no. 87, pp. 405-14. doi: 10.2183/pjab.87.405.
17. Watabe H., Mitsushima T., Yamaji Y., et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005, no. 54, pp. 764-8. doi: 10.1136/gut.2004.055400.
18. Leung W. K., Wu M. S., Kakugawa Y., et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncology. 2008, no. 9, pp. 279-87. doi: 10.1016/S1470-2045(08)70072-X.
19. Chen W., Zheng R., Baade P. D., et al. Cancer statistics in china, 2015. CA: a cancer journal for clinicians. 2016, no. 66, pp. 115-32. doi: 10.3322/caac.21338.
20. Chun N., Ford J. Genetic testing in stomach cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.
21. Rawla P., Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Przeglad Gastroenterologiczny. 2019, no. 14, pp. 26-38. doi: 10.5114/pg.2018.80001.
22. Correa P. The biological model of gastric carcinogenesis. JARC Scientific publications. 2004, no. 157, pp. 301-310. PMID: 15055303.
23. Sipponen P. Gastric cancer: pathogenesis, risks, and prevention. Journal gastroenterology. 2002, no. 37, pp. 39-44. doi: 10.1007/BF02990098.
24. Sipponen P., Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer. 2002, no. 5, pp. 213-9.
25. Ma L., Chow J. Y., Cho C. H. Effects of cigarette smoking on gastric ulcer formation and healing: possible mechanisms of action. Jornal of clinical gastroenterology. 1998, no. 27, pp. 80. doi: 10.1097/00004836-199800001-00013.
26. Ferro A., Morais S., Rota M., et al. Tobacco smoking and gastric cancer: meta-analyses of published data versus pooled analyses of individual participant data. European journal of cancer prevention. 2018, no. 27, pp. 197-204. doi: 10.1097/CEJ.0000000000000401.
27. Han F., Wang X., Wang X., et al. Meta-analysis of the association of cYP1a1 polymorphisms with gastric cancer susceptibility and interaction with tobacco smoking. Molecular Biology Reports. 2012, no. 39, pp. 8335-8344. doi: 10.1007/s11033-012-1683-z.
28. La TorreG., Chiaradia G., Gianfagna F., et al. Smoking status and gastric cancer risk: an updated meta-analysis of case-control studies published in the past ten years. Tumori. 2009, no. 95, pp. 13-22. doi: 10/1700/410.4843.
29. Ladeiras-Lopes R., Kirchhofer Pereira A., Nogueira A., et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control. 2008, no. 19, pp. 689-701. doi: 10.1007/s10552-008-9132-y.
30. Tsugane S., Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer. 2007. 10(2):75-83. doi: 10.1007/s10120-007-0420-0.
31. Gotoda T., Yanagisawa A., Sasako M., et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000, no. 3, pp. 219-225. doi: 10.1007/pl00011720.
32. Chernousov A., Polikarpov S., Gozhelo E. Early cancer and precancerous diseases of the stomach. Moscow. IzdAT Publ., 2002, 256 P. (in Russ.) ISBN 5-86656-136-0. @@Черноусов А. Ф., Поликарпов С. А., Годжело Э. А. Ранний рак и предопухолевые заболевания желудка - М.: ИздАТ, 2002. -256 с.
33. Nashimoto A., Akazawa K., Isobe Y., et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013, no.16, pp. 1-27. doi: 10.1007/s10120-012-0163-4
34. Schepotin I., Evans S. Stomach cancer: a practical guide to prevention, diagnosis and treatment. Kiev “Book Plus” 2000, 227 P. (in Russ.) ISBN 966-7619-00-1. @@Щепотин И. Б., Эванс С. Р. Рак желудка: практическое руководство по профилактике, диагностике и лечению. Киев “Книга Плюс” 2000. - 227 с.
35. Besova N., Tryakin A., Artamonova E., et al. Practical recommendations for drug treatment of stomach cancer. Malignant tumors. 2020;10(3s2-1): 334-349. (in Russ.) doi: 10.18027 / 2224-5057-2020-10-3s2-21. @@Бесова Н. С., Трякин А. А., Артамонова Е. В. и др. Практические рекомендации по лекарственному лечению рака желудка. Злокачественные опухоли. 2020;10(3s2-1):334-349. doi: 10.18027/2224-5057-2020-10-3s2-21.
36. Xiao Hua, Zhonghua Nei, Jing Za Zhi. Сonsensus on screening and endoscopic diagnosis and treatment of early gastric cancer in Сhina (Сhangsha, 2014). Сhinese Society of Digestive endoscopy. 2014, no. 31, pp. 361-77. doi: 10.3969/j.issn.1008-7125.2014.07.006.
37. Zaridze D. Epidemiology and etiology of malignant diseases. Carcinogenesis. Moscow. Scientific world Publ., 2000. @@Заридзе Д. Г. Эпидемиология и этиология злокачественных заболеваний// Заридзе Д. Г. Канцерогенез. - Москва: Научный мир, 2000.
38. Tsugane S., Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer. 2007, no. 10, pp. 75-83. doi: 10.1007/s10120-007-0420-0.
39. Rumgay H., Shield K., Charvat H., et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol. 2021, no. 22, pp. 1071-1080. doi: 10.1016/S1470-2045(21)00279-5.
40. Nelson D. E., Jarman D. W., Rehm J., et al. Alcohol-Attributable Cancer Deaths and Years of Potential Life Lost in the United States. American journal of public health. 2013, no. 103, pp. 641-648. doi: 10.2105/AJPH.2012.301199.
41. Inoue M., Iwasaki M., Otani T., et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Archives of internal medicine. 2006, no. 166, pp. 1871-7. doi: 10.1001/archinte.166.17.1871.
42. Yang P., Zhou Y., Chen B., et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Europian journal of cancer. 2009, no. 45, pp. 2867-2873. doi: 10.1016/j.ejca.2009.04.019.
43. Taninaga J., Nishiyama Y., Fujibayashi K., et al. Prediction of future gastric cancer risk using a machine learning algorithm and comprehensive medical check-up data: A case-control study. Scientific reports. 2019, no. 9, pp. 12384. doi: 10.1038/s41598-019-48769-y.
44. Nie Y., Wu K., Yu J., et al. a global burden of gastric cancer: the major impact of china. Expert Rev Gastroenterol Hepatol, 2017, no. 11, pp. 651-61. doi: 10.1080/17474124.2017.1312342.
45. Cai Q., Yu E. D., Xiao Y., et al. Derivation and validation of a prediction rule for estimating advanced colorectal neoplasm risk in average-risk chinese. Am J Epidemiol. 2012; 175:584-93. doi: 10.1093/aje/kwr337.
46. Zagari rM., Rabitti S., Greenwood Dc., et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and antiHelicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017; 46:657-67. doi: 10.1111/apt.14248.
47. Leung W. K., Wu M. S., Kakugawa Y., et al. Asia Pacific Working Group on Gastric Cancer. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008; 9:279-87. doi: 10.1016/S1470-2045(08)70072-X.
48. Chiang T.H., Chiu S. Y., Chen S.l., et al. Serum Pepsinogen as a Predictor for gastric cancer Death: a 16-Year community-based cohort Study. J Clin Gastroenterol. May/Jun 2019;53(5): e186-e193. doi: 10.1097/MCG.000000000000099.
49. Lin E., Bian H., Chen C., et al. Application of serum pepsinogen and carbohydrate antigen 72-4 (CA72-4) combined with gastrin-17 (G-17) detection in the screening, diagnosis, and evaluation of early gastric cancer. J Gastrointest Oncol. 2021 Jun; 12(3): 1042-1048. doi: 10.21037/jgo-21-254.
50. Karimi P., Islami F., Anandasabapathy S., et al. gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700-13. doi: 10.1158/1055-9965.EPI-13-1057.
51. Sun L., Tu H., Liu J., et al. A comprehensive evaluation of fasting serum gastrin-17 as a predictor of diseased stomach in chinese population. Scand J Gastroenterol. 2014;49:1164-72. doi: 10.3109/00365521.2014.950693.
52. Kurilovich S, Belkovets A, Reshetnikov O., et al. Stomach-specific Biomarkers (gastroPanel) can Predict the Development of gastric cancer in a caucasian Population: a longitudinal nested case-control Study in Siberia. Anticancer Res. 2016;36:247-53. PMID: 26722050.
53. Haj-Sheykholeslami A., Rakhshani N., Amirzargar A., et al. Serum pepsinogen i, pepsinogen ii, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol. 2008;6:174-9. doi: 10.1016/j.cgh.2007.11.016.
54. Sawada M., Dickinson C. J. The G-cell. Annu Rev Physiol. 1997; 59:273-98. doi: 10.1146/annurev.physiol.59.1.273.
55. Wang T. C., Dangler C. A., Chen D., et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology. 2000; 118:36-47. doi: 10.1016/s0016-5085(00)70412-4.
56. Silvis S., Nebel E., Rogers O., et al. Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy Survey. JAMA. 1976, no. 235, pp. 928-930. doi: 10.1001/jama.235.9.928.
57. ASGE Standards of Practice Committee, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest. Endosc. 2015; 82: 1-8, doi: 10.1016/j.gie.2015.03.1967.
58. Correa P. A human model of gastric carcinogenesis. Cancer Research. 1988, no. 48, pp. 3554-3560. PMID: 3288329.
59. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 1994, 61, 1-241. PMCID: PMC7681621.
60. Vannella L., Lahner E., Osborn J., Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Alimentary pharmacology and therapeutics. 2013. no. 37, pp. 375-382. doi: 10.1111/apt.12177.
61. Feng F., Zheng G., Wang Q., et al. Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer. BMC Gastroenterology. 2018. no. 18, pp. 148. doi: 10.1186/s12876-018-0877-9.
62. Jiang Y., Xu H., Jiang H., Ding S., Zheng T. Pretreatment neutrophil-lymphocyte count ratio may associate with gastric cancer presence. Cancer biomarkers: section A of disease markers. 2016. no. 16, pp. 523-528. doi: 10.3233/CBM-160593.
63. Takeno S., HashimotoT., Maki K., et al. Gastric cancer arising from the remnant stomach after distal gastrectomy: a review. World journal of gastroenterology. 2014. no. 20, pp. 13734-13740. doi: 10.3748/wjg.v20.i38.13734.
64. Ilson D. H. Advances in the treatment of gastric cancer. Curr. Opin. Gastroenterol. 2018; 33: 473-476. doi: 10.1097/MOG.0000000000000475.
65. Boland C. R., Yurgelun M. B. Historical perspective on familial gastric cancer. Cell Mol Gastroenterol Hepatol. 2017;3:192-200. doi: 10.1016/j.jcmgh.2016.12.003.
66. Li J., Woods S. L., Healey S., et al. Point mutations in exon 1B of APC reveal gastric adenocarcinoma and proximal polyposis of the stomach as a familial adenomatous polyposis variant. Am J Hum Genet. 2016; 98:830-42. doi: 10.1016/j.ajhg.2016.03.001.
67. World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Continuous Update Project Report: Diet, Nutrition, Physical Activity and Stomach Cancer, 2016. Revised 2018.
68. Balakrishnan M., George R., Sharma A., Graham D. Y. Changing trends in stomach cancer throughout the world. Current gastroenterology reports. 2017. No. 19, pp. 36. doi: 10.1007/s11894-017-0575-8.
69. Avanesyan A., Sokolenko A., Ivantsov A., et al. Stomach cancer in carriers of the BRCA1 germline mutation: results of endoscopic screening and molecular analysis of tumor tissues. Pathobiology, 2020, no. 87, pp. 367-374. (in Russ.) doi: 10.1159/000511323. @@Аванесян А. А., Соколенко А. П., Иванцов А. И. и др. Рак желудка у носителей мутации зародышевой линии BRCA1: результаты эндоскопического скрининга и молекулярного анализа опухолевых тканей/ Патобиология, 2020. - № 87 (6), с. 367-374.
70. Ilson D. H. Advances in the treatment of gastric cancer. Curr. Opin. Gastroenterol. 2017. 33, 473-476. doi: 10.1097/MOG.0000000000000395.
71. Leja M., You W., Camargo M. C., et al. Implementation of gastric cancer screening - the global experience. Best Pract Res Clin Gastroenterol. 2014;28:1093-106. doi: 10.1016/j.bpg.2014.09.005.
72. Kim G. H., Liang P. S., Bang S. J., Hwang J. H. Screening and surveillance for gastric cancer in the United States: Is it needed? Gastrointestinal endoscopy. 2016. no. 84, pp.18-28. doi: 10.1016/j.gie.2016.02.028.
73. González C. A., Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go.Int J Cancer, 2012; 130:745-53. doi: 10.1002/ijc.26430.
Review
For citations:
Baranovskiy A.Yu., Tcvetkova T.L. Risk factors of gastric cancer as a basis for the development of a prognostic questionnaire for the register of patients with precancerous gastroduodenal diseases. Experimental and Clinical Gastroenterology. 2022;(9):29-38. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-205-9-29-38
Views:
292
Email this article 